The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Interleukin-4 mediates the neuroprotective effects of rosiglitazone in the aged brain.
David J Loane; Brian F Deighan; Rachael M Clarke; Rebecca J Griffin; Aileen M Lynch; Marina A Lynch (Profiled Author: David J Loane)
Trinity College Institute for Neuroscience and Physiology Department, Trinity College, Dublin 2, Ireland.
Neurobiology of aging 2009;30(6):920-31.
Increased expression of proinflammatory cytokines, like interleukin-1 beta (IL-1 beta), is a feature of the aged brain and it is generally accepted that the primary cell source of these cytokines is activated microglia. In hippocampus of aged rats, the increase in IL-1 beta is accompanied by microglial activation and impaired long-term potentiation (LTP). Peroxisome proliferator-activated receptors (PPARs) possess anti-inflammatory properties that target microglia. In this study the PPAR gamma agonist, rosiglitazone, was orally administered to young and aged rats, and we report that the age-related increases in NO and IL-1 beta production were attenuated in hippocampus of rosiglitazone-treated aged rats and that this was associated with a restoration of LTP. In addition, treatment with rosiglitazone increased interleukin-4 (IL-4) mRNA and reversed the age-related decrease in hippocampal IL-4 concentration. Significantly, while rosiglitazone attenuated the LPS-induced increase in MHCII and IL-1 beta concentration in glia prepared from wildtype mice, it failed to exert an effect in glia prepared from IL-4(-/-) mice, thereby suggesting that the anti-inflammatory actions of rosiglitazone are mediated by its ability to increase IL-4 expression.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Aileen M Lynch; David J Loane; Aedín M Minogue; Rachael M Clarke; Dana Kilroy; Rachel E Nally; Oran J Roche; Florence O'Connell; Marina A LynchNeurobiology of aging 2007;28(6):845-55.
Aedín M Minogue; Aileen M Lynch; David J Loane; Caroline E Herron; Marina A LynchJournal of neurochemistry 2007;103(3):914-26.
Soren Snitker; Richard M Watanabe; Ifeanyi Ani; Anny H Xiang; Aura Marroquin; Cesar Ochoa; Jose Goico; Alan R Shuldiner; Thomas A Buchanan;
Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study.Diabetes care 2004;27(6):1365-8.
Appears in this Publication
Author of this Publication